Education
About Us
Working with TipRanks
Follow Us
Pharming Group (NL:PHARM)
:PHARM
Earnings Data
Report Date
Mar 12, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
<0.01Last Year’s EPS
<0.01Same Quarter Last Year
Moderate Buy
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance with significant revenue growth and upgraded guidance. RUCONEST and Joenja both showed robust performance, and the company's cash position has been restored. However, there is a planned withdrawal of RUCONEST from certain markets due to financial sustainability concerns. Overall, the positive aspects significantly outweigh the lowlight.Company Guidance
Strong Revenue Growth
Total revenues grew by 30% in Q3 2025 versus the same quarter last year, and operating profit jumped to $15.8 million, nearly 4x last year's result.
RUCONEST and Joenja Performance
RUCONEST revenue grew 29% year-on-year, driven by new prescribers and patient enrollments. Joenja third quarter revenue increased by 35%, reflecting strong patient growth and new patient identification.
Upgraded Revenue Guidance
The company raised its full-year 2025 revenue guidance to $365 million to $375 million from the previous $335 million to $350 million.
Cash Position Recovery
Operating cash flow was $32 million, bringing the cash position nearly back to its level before the Abliva acquisition at the end of 2024.
Pipeline Advancements
Progress in the pipeline includes Phase II proof-of-concept studies for PIDs with immune dysregulation, and a registrational study for KL1333 in primary mitochondrial disease.
NL:PHARM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NL:PHARM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 06, 2025 | €1.10 | €1.37 | +24.25% |
Jul 31, 2025 | €0.85 | €0.97 | +14.15% |
May 08, 2025 | €0.76 | €0.89 | +16.64% |
Mar 13, 2025 | €0.72 | €0.84 | +16.43% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Pharming Group (NL:PHARM) report earnings?
Pharming Group (NL:PHARM) is schdueled to report earning on Mar 12, 2026, Before Open (Confirmed).
What is Pharming Group (NL:PHARM) earnings time?
Pharming Group (NL:PHARM) earnings time is at Mar 12, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Pharming Group stock?
The P/E ratio of Pharming Group is N/A.
What is NL:PHARM EPS forecast?
NL:PHARM EPS forecast for the fiscal quarter 2025 (Q4) is <0.01.